Table 2.
Anticancer drug clinically used and/or tested for HAI administration.
| Anticancer Drug | Pharmacologic Class | Hepatic Extraction Rate | References |
|---|---|---|---|
| Floxuridine | Antimetabolite (pyrimidine analogue) | 95% | Kemeny et al. (1986) [63] |
| 5-Fluorouracile | Antimetabolite (pyrimidine analogue) | 75–80% | Technical Sheet [64,65] |
| Doxorubicin | Intercalating antibiotic (anthracycline) | Up to 81.2% (in dogs) | Iwasaki et al. (1998) [70] |
| Epirubicin | Intercalating antibiotic (anthracycline) | 60% | Cantore et al. (2005) [68] |
| Oxaliplatin | Alkylating agent (platinum salt) | 47% | Guthoff et al. (2003) [72] |
| Cisplatin | Alkylating agent (platinum salt) | 24 ± 9% | Campbell et al. (1983) [74] |
| Gemcitabine | Antimetabolite (nucleoside analogue) | 55–89% (dose-dependent) | Von Riel et al. (2009) [77] |
| Irinotecan | Topoisomerase I inhibitor (camptothecin) | N.D. | - |